• Revenue growth of 19% vs prior comparative period
• EBITDA margin improved from -2% to 11%
• Positive operating and free cash flow

SomnoMed Ltd, a leading provider of oral sleep devices, has reported a strong set of financial results for the first half of the 2025 financial year. The company's revenue grew by 19% compared to the prior comparative period, driven by double-digit growth across all regions. This revenue growth, combined with disciplined cost management, resulted in a significant improvement in EBITDA margin from -2% in H1 FY24 to 11% in H1 FY25. SomnoMed also generated positive operating cash flow of $4.1 million and free cash flow of $1.3 million, representing improvements of $8.7 million and $9.3 million respectively compared to the prior comparative period. The company's balance sheet was further strengthened, with cash and cash equivalents increasing to $18.5 million as of 31 December 2024. SomnoMed has also made significant progress on its operational initiatives, including reducing manufacturing production backlog from over 2 weeks to less than 2 days and turnaround time from over 3 weeks to less than 10 days. The company has also bolstered its leadership team with the addition of several experienced executives, and has strengthened its Board of Directors with the appointment of individuals with deep sector, manufacturing, and investment experience.

For FY25, SomnoMed expects revenue of around $105 million and EBITDA in the range of $7-9 million. Capital expenditure is expected to be $3-4 million.

SomnoMed is focused on delivering sustainable growth and innovation, with priorities including returning to double-digit revenue growth, achieving EBITDA margins of 10% or more, and launching its new Rest Assure product.